January 12, 2021
Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
FREDERICK, Md – January 12, 2021 – Veralox Therapeutics, a biotechnology company developing first-in-class small…